Both hypo- and hyperkalemia are associated with adverse events in heart failure patients. Their effects on patients with left ventricular assist devices (LVADs) remains unknown. The cohort included consecutive patients undergoing LVAD implantation between 2014 and 2018. In all, 170 patients (median age 56 years; 117 males) were stratified according to serum potassium levels 1 month after implantation into 3 groups: hypokalemia (<3.5 mEq/L; n=15), normokalemia (n=146), and hyperkalemia (>5.0 mEq/L; n=9). Compared with the normokalemia group, the adjusted hazard ratios for 1-year mortality were 0.91 (95% confidence interval [CI] 0.21-3.92) for hypokalemia and 4.14 (95% CI 1.47-11.65) for hyperkalemia. In the hyperkalemia group, the prevalence of renin-angiotensin-aldosterone system inhibitors decreased and serum potassium levels normalized following the first month. Hyperkalemia was associated with increased mortality during LVAD support. Management of serum potassium needs further investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578129 | PMC |
| http://dx.doi.org/10.1253/circrep.CR-21-0078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Navigating Hyperkalaemia- The A-to-H Clinical Strategy.
J Pak Med Assoc
January 2025
Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India.
Hyperkalaemia is a life-threatening dyselectrolytaemia which is characterized by elevated serum potassium levels. It needs a systematic and overarching approach to effectively manage a case of hyperkalaemia. We propose a structured A-to-H approach to guide clinicians in managing hyperkalaemia, ensuring that no critical aspect is neglected or inadvertently missed.
View Article and Find Full Text PDFManagement of haemolysis-induced hyperkalaemia in an extremely low birthweight infant exposed to maternal sulfasalazine.
BMJ Case Rep
January 2025
Neonatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Sulfasalazine is a non-specific immunomodulator with haemolytic anaemia as a known side effect that crosses the placenta. We present a preterm neonate with cardiac arrhythmia secondary to hyperkalaemia in the setting of maternal sulfasalazine therapy. A preterm infant was born to a mother taking hydroxychloroquine, sulfasalazine, aspirin and enoxaparin throughout pregnancy.
View Article and Find Full Text PDFSacubitril/Valsartan for Blood Pressure Lowering in Non-Dialysis-Dependent Chronic Kidney Disease Stage 3-5 Patients With Hypertension: A Multicenter Clinical Study.
J Clin Hypertens (Greenwich)
January 2025
Department of Nephrology, Southeast University Zhongda Hospital, Southeast University School of Medicine, Nanjing, China.
To assess the effectiveness and safety of Sacubitril/Valsartan in reducing blood pressure in individuals with non-dialysis-dependent chronic kidney disease (NDD-CKD) Stage 3-5 complicated by hypertension. This study was a multicenter retrospective analysis conducted from March 1, 2022 to March 31, 2024, involving adult patients with NDD-CKD Stage 3-5 and hypertension, who received Sacubitril/Valsartan either as a monotherapy or in addition to current antihypertensive treatments that were insufficient. The main outcomes measured were blood pressure control, changes in blood pressure and laboratory parameters within 8 weeks post-treatment initiation, and incidence of adverse events.
View Article and Find Full Text PDFThe effect of different timings of protein supplementation on variable outcomes in hemodialysis patients: a randomized clinical trial.
Clin Exp Nephrol
January 2025
Internal Medicine Department, El Qabbary General Hospital, Ministry of Health, Alexandria, Egypt.
Background: Oral nutritional supplements (ONS) are commonly prescribed to provide protein and energy to hemodialysis (HD) patients. There is a debate about the appropriate timing to administer ONS. We aimed to study the effect of different timings of ONS on variable outcomes in HD patients.
View Article and Find Full Text PDFSudden Cardiac Arrest Associated with Hemodialysis: A Community-Based Study.
Kidney360
January 2025
Center for Cardiac Arrest Prevention, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Health System, Los Angeles, CA, United States.
Background: Individuals with end-stage renal disease may be at increased risk of sudden cardiac arrest (SCA) associated with dialysis therapy. However, community-based studies with comprehensive adjudication of SCA are lacking.
Methods: We conducted a community-based study using a case-case study design in a US population of ≈1 million.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!